Englitazone

Englitazone is a thiazolidinedione derivative, which is a type of antidiabetic drug. It was developed by Eli Lilly and Company but was never marketed.

Mechanism of Action

Englitazone works by activating peroxisome proliferator-activated receptors (PPARs), specifically PPARγ. PPARs are a group of nuclear receptor proteins that function as transcription factors regulating the expression of genes. PPARγ activation results in an increase in the transcription of insulin-responsive genes, leading to better cellular response to insulin.

Pharmacokinetics

The pharmacokinetics of englitazone, like other thiazolidinediones, involves absorption in the gastrointestinal tract after oral administration. It is extensively metabolized in the liver and excreted in the urine and feces.

Side Effects

Potential side effects of englitazone include weight gain, edema, and potential increase in cardiovascular disease risk. It may also cause or exacerbate congestive heart failure in some patients.

Development and Marketing

Englitazone was developed by Eli Lilly and Company but was never marketed. The reasons for this are not publicly disclosed, but may be related to the side effect profile or market competition.

See Also

• Thiazolidinedione
• Peroxisome proliferator-activated receptors
• Insulin resistance
• Type 2 diabetes

Englitazone Resources
Latest articles Most recent articles Ongoing trials	Wikipedia